New robotic technology launched in Glasgow hospital for knee replacements
Ross Hall Hospital, part of Circle Health Group, is said to be the only private hospital in Scotland to offer the VELYS Robotic-Assisted Solution.
Developed by Johnson & Johnson MedTech, the system is designed to improve patient outcomes with shorter hospital stays and greater post-surgery mobility.
Mhairi Jefferies, executive director of Ross Hall Hospital, said: "We are delighted to be working with Johnson & Johnson MedTech to deploy the VELYS system at Ross Hall Hospital.
Read more:
Vile rapist sentenced after preying on two young girls
"We know our patients are looking for faster recovery times and an improved quality of life post-surgery.
"The arrival of this system promises to offer our patients the latest and best technology on their doorstep."
The VELYS system works exclusively with the ATTUNE Knee System and is designed to improve post-operative stability and movement by preserving soft tissue around the knee joint.
It uses CT-free technology to assist surgeons in placing implants more accurately, aiming for more predictable outcomes and a quicker return to mobility.
The first procedure using the new technology was carried out on April 23.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Swinney ‘supports' NHS Fife after trans medic row nurse cleared of misconduct
Scotland's First Minister has insisted he has confidence in the health board at the centre of an employment tribunal brought after a transgender doctor was allowed to use a female changing room at a hospital. Nurse Sandie Peggie complained about Dr Beth Upton being granted access to female changing facilities, and has taken Dr Upton and bosses at NHS Fife to an employment tribunal. As tribunal proceedings resumed on Wednesday, it emerged Ms Peggie has been cleared of gross misconduct allegations following a separate disciplinary hearing by the health board. Scottish Conservative equalities spokeswoman Tess White said: 'This decision confirms what we've known all along – Sandie Peggie did nothing wrong. 'NHS Fife's credibility lies in tatters and senior bosses owe Sandie an immediate and unreserved apology.' First Minister John Swinney however insisted: 'NHS Fife has my confidence and support. 'They've got important work to do to deliver for the healthcare needs people of Fife, and that's what I expect them to.' He said the disciplinary process had 'examined issues about the alleged conduct of Sandie Peggie' and had now 'reached its conclusion'. The First Minister added: 'It is important that these processes are fair to all parties and that is what has been taken forward here and it has reached its conclusion. 'There is obviously an employment tribunal that has been brought by Sandie Peggie that is currently under way. 'It's not appropriate for me to comment on the live proceedings that are under way in that process.' Scottish Conservative deputy leader Rachael Hamilton said: 'It's frankly astonishing that John Swinney is still backing this discredited health board to the hilt. 'They've dragged a dedicated nurse through a traumatic disciplinary hearing and tried to cover up the hundreds of thousands they have already squandered on this tribunal. 'SNP ministers have ignored countless warnings that NHS Fife was failing to comply with their legal obligations. 'It raises a serious question, what exactly would this health board have to do to lose the First Minister's confidence? 'Instead of defending the indefensible, John Swinney should finally stand on the side of women and girls and ensure that NHS Fife and other public bodies are following the law by always providing single-sex spaces.'
Yahoo
an hour ago
- Yahoo
Verona Pharma plc (VRNA): A Bull Case Theory
We came across a bullish thesis on Verona Pharma plc (VRNA) on Capital Employed's Substack by Patients Capital Management. In this article, we will summarize the bulls' thesis on VRNA. Verona Pharma plc (VRNA)'s share was trading at $91.53 as of 3rd July. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Verona Pharma, a UK-based biopharmaceutical company, is advancing a standout therapeutic with its lead asset, Ohtuvayre, poised to redefine treatment for COPD and related respiratory diseases. The most compelling data point is patient feedback: individuals using Ohtuvayre report feeling noticeably better, which is critical in COPD where managing daily wellbeing matters most. Ohtuvayre's non-steroidal mechanism means it can be safely combined with all existing COPD medications, creating effectively zero competition and addressing a major unmet need by avoiding the downsides of chronic steroid therapies. Beyond COPD, Verona Pharma retains significant upside from potential indications in non-CF bronchiectasis and asthma, which remain largely unpriced in current valuations and could offer meaningful long-term growth—serving as optionality embedded in the investment thesis. Strategically, the company is positioning for partnerships by developing dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations, creating a clear window for larger pharmaceutical companies to engage in due diligence or acquisition discussions. Importantly, Verona Pharma carries no near-term financing overhang, eliminating a common investor concern and making potential deal outcomes even more impactful. Despite a strong rally in the stock, the market still appears to underappreciate Verona Pharma's potential: analysts are currently modeling peak sales of around $2.5 billion, even though the nebulized version alone could realistically reach $4–5 billion. As sell-side estimates adjust quarterly to reflect this upside, the stock is likely to re‐rate. Looking ahead, growing investor conviction and evolving shareholder base could provide deeper support for higher valuation levels. With differentiated clinical efficacy, broad strategic optionality, strong balance sheet, and significant valuation mispricing, Verona Pharma offers a compelling multi-catalyst investment opportunity in respiratory therapeutics. Previously, we covered a on Teva Pharmaceutical Industries Limited (TEVA) by Kontra in May 2025, which highlighted the company's transformation under CEO Richard Francis, strong free cash flow growth, and rising contributions from innovative drugs like Austedo and Uzedy. The company's stock price has been stable with an approximate 0.7% gain since our coverage. This is because the thesis has yet to fully play out but remains valid given Teva's ongoing operational momentum and valuation support. Patients Capital Management shares a similar view on Verona Pharma but emphasizes a more targeted bet on a single asset, Ohtuvayre, with blockbuster potential and strategic optionality in respiratory therapeutics. VRNA isn't on our list of the 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the risk and potential of VRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
NHS Fife equality lead sought guidance on trans staff policies, tribunal told
NHS Fife's equality lead sought guidance from other health boards before advising that a transgender doctor could use a female changing room, a tribunal has heard. Nurse Sandie Peggie was suspended from work at the Victoria Hospital in Kirkcaldy, Fife, on January 3, 2024 after she complained about having to share a changing room with trans medic Dr Beth Upton. After Dr Upton made an allegation of bullying and harassment and cited concerns about 'patient care', Ms Peggie was suspended but was notified of safety allegations on March 28, 2024 in a letter, the tribunal heard earlier this year. Ms Peggie has lodged a claim against Fife health board and Dr Upton, citing the Equality Act 2010, including sexual harassment; harassment related to a protected belief; indirect discrimination and victimisation. The tribunal in Dundee resumed on Wednesday after previous hearings in February, and comes after the UK Supreme Court ruled in April that the terms 'woman' and 'sex' in the 2010 Equality Act 'refer to a biological woman and biological sex', a ruling which has been publicly welcomed by Ms Peggie. Isla Bumba, NHS Fife's equality and human rights lead officer, told the tribunal on Wednesday she researched the policies of other health boards as there was no regional policy in place regarding trans employees in 2023. Questioned by NHS Fife's counsel Jane Russell KC, Ms Bumba said that in August 2023, her line manager Esther Davidson had sought advice on transgender policies. Ms Bumba said: 'Esther called me, I believe she had called me to ask for very generic and informal advice. I was told they had a transgender staff member who was due to join the workforce, she was seeking advice on how best to accommodate them particularly around changing rooms.' She added: 'I said it could be deemed discriminatory to not allow a trans person access to facilities that aligned with their gender, but I recommended that it might be worthwhile having a conversation with the person directly if they had been open about their trans status to see where they would be most comfortable.' Ms Bumba said she looked at policies from NHS Lanarkshire and NHS Highland, and was regularly communicating with peers in her role as part of the NHS Scotland Equality Leads Network, and she was also working on a draft patient policy. Ms Russell read from the NHS Highland policy which said: 'Staff must be treated in accordance with self-declared gender regardless of whether under medical supervision or having gender recognition certificate.' Ms Bumba said the policy 'exactly' aligned with her understanding, and at the time, a national policy Once For Scotland from NHS Scotland was being worked on in draft form. She said she believed the national policy had been 'soft launched' before being withdrawn in February 2025 due to legal proceedings. Ms Bumba said she was providing advice on trans issues 'relatively frequently… at least once a month or every couple of weeks', and she believed Dr Upton was not the only transgender employee at NHS Fife. Ms Bumba said she was contacted by Dr Upton's line manager, Dr Kate Searle, on December 8 2023, and referred to the draft national policy. Ms Bumba went on annual leave between December 24 that year until January 3 2024, when she said she became aware of a conflict between a doctor and a nurse. She told the tribunal she read a Datix report titled 'hate incident' and read an email from Dr Searle on January 8, and offered to have a chat 'to see what the plan was moving forward'. However she said this meeting did not happen as it was 'chaotic', and Dr Searle was off the following day. She said she had previously advised two line managers to speak to HR but believed they had already done so in her absence. Ms Bumba said: 'I believe the advice I gave was that from the information I'd been given it sounded like a very unpleasant incident, it could be deemed discriminatory and I recommended they seek advice from HR. 'I believe the Datix was listed as a hate incident which would suggest the person who listed it believed it was discriminatory.' However she said she had no further involvement until July 2024 when a press report prompted a meeting. Ms Bumba said: 'I did remind the group that the nurse involved was entitled to her beliefs and that gender-critical beliefs were protected under the Equality Act, but that the NHS expects staff to behave with care and compassion.' She said the draft patient policy was put on hold and NHS Fife was 'hesitant' about the draft national policy, the tribunal heard. Ms Bumba said: 'I believe the soft launch has been pulled since the onset of this tribunal.' Hours before the tribunal was due to restart, Ms Peggie's solicitor Margaret Gribbon said the nurse had been cleared of gross misconduct allegations following a separate health board disciplinary hearing. The inquiry continues.
